Portefeuille d'ETF XBI (NYSE) - Page 5 | MetaTrader

Afficher le graphique complet Full chart

Aperçu Toutes les participations Heatmap

Principaux titres en portefeuille Market Value Shares Weight %

DNTH Dianthus Therapeutics Inc 39.5 M 958.9 K 0.5%

BHVN Biohaven Ltd 39.2 M 3.5 M 0.5%

ARDX Ardelyx Inc 37.7 M 6.5 M 0.5%

RCUS Arcus Biosciences Inc 36.7 M 1.5 M 0.5%

NVAX Novavax Inc 36.7 M 5.5 M 0.5%

TNGX Tango Therapeutics Inc 33.3 M 3.8 M 0.4%

KURA Kura Oncology Inc 32.3 M 3.1 M 0.4%

NTLA Intellia Therapeutics Inc 32.1 M 3.6 M 0.4%

IOVA Iovance Biotherapeutics Inc 32.0 M 11.7 M 0.4%

TSHA Taysha Gene Therapies Inc 31.4 M 5.7 M 0.4%

RIGL Rigel Pharmaceuticals Inc 30.6 M 714.1 K 0.4%

SYRE Spyre Therapeutics Inc 29.0 M 884.9 K 0.4%

NRIX Nurix Therapeutics Inc 28.5 M 1.5 M 0.4%

CDNA CareDx Inc 28.4 M 1.5 M 0.4%

ANAB AnaptysBio Inc 28.4 M 585.1 K 0.4%

KOD Kodiak Sciences Inc 27.6 M 986.2 K 0.4%

PVLA Palvella Therapeutics Inc 27.3 M 260.7 K 0.3%

RLAY Relay Therapeutics Inc 27.2 M 3.2 M 0.3%

PGEN Precigen Inc 25.9 M 6.2 M 0.3%

XNCR Xencor Inc 24.8 M 1.6 M 0.3%

1
2
3
4
5
6
7
8

Nouvelles

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Jefferies abaisse la note de Tango Therapeutics en raison de la valorisation

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

La vente à découvert d’Intellia progresse le plus parmi les biotechs

What's The Dominant Trend In Earnings: AI Or Geopolitics?